Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 1.00 |
| ▸ | KDM6B | O15054 | 1/20 | 1.00 |
| ▸ | TET3 | O43151 | 1/20 | 1.00 |
| ▸ | KDM4A | O75164 | 1/20 | 1.00 |
| ▸ | KDM4B | O94953 | 1/20 | 1.00 |
| ▸ | KDM5A | P29375 | 1/20 | 1.00 |
| ▸ | KDM5C | P41229 | 1/20 | 1.00 |
| ▸ | KDM4D | Q6B0I6 | 1/20 | 1.00 |
| ▸ | TET2 | Q6N021 | 1/20 | 1.00 |
| ▸ | TET1 | Q8NFU7 | 1/20 | 1.00 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 1.00 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.55 |
| ▸ | GAA | P10253 | 3/20 | 0.55 |
| ▸ | MEN1 | O00255 | 3/20 | 0.55 |
| ▸ | ALOX12 | P18054 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | AGTR1 | P30556 | 4/20 | 0.52 |
| ▸ | RAB9A | P51151 | 5/20 | 0.51 |
| ▸ | NPC1 | O15118 | 4/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29382353 | 1.00 | KDM4E (1.00) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL17670545 | 1.00 | KDM4E (1.00) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL20214000 | 1.00 | KDM4E (1.00) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL29353093 | 1.00 | KDM4E (1.00) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL30539398 | 0.92 | KDM4E (0.85) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL4926318 | 0.84 | KDM4E (0.72) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL20101080 | 0.84 | KDM4E (0.72) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL18159120 | 0.84 | KDM4E (0.73) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL31237795 | 0.81 | KDM4E (0.68) | KDM4EKDM6BTET3KDM4AKDM4B | |
| SCHEMBL20101021 | 0.79 | KDM4E (0.65) | KDM4EKDM6BTET3KDM4AKDM4B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 41 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250160275-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-22 | — | — | US | claimed |
| WO-2024211130-A1 | METHODS FOR MODIFYING MEIOTIC RECOMBINATION IN PLANTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-10-10 | — | — | WO | claimed |
| WO-2023164606-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2023-08-31 | — | — | WO | claimed |
| US-20200155526-A1 | TARGETING LYSINE DEMETHYLASES (KDMS) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA | THE CHILDREN'S MEDICAL CENTER CORPORATION (US) | 2020-05-21 | — | — | US | claimed |
| EP-4194548-B1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH INC (US) | 2025-10-22 | — | — | EP | disclosed |
| US-20250160275-A1 | COMPOUNDS FOR MODIFYING MEIOTIC RECOMBINATION AND METHODS RELATING THERETO | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL | 2025-05-22 | — | — | US | disclosed |
| WO-2024211130-A1 | METHODS FOR MODIFYING MEIOTIC RECOMBINATION IN PLANTS | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2024-10-10 | — | — | WO | disclosed |
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | THE WISTAR INSTITUTE OF ANATOMY AND BIOLOGY | 2024-05-02 | — | — | US | disclosed |
| EP-3664789-B1 | METHODS FOR TREATING DISEASES AND NERVE INJURY | CHILDRENS HOSPITAL MED CT (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-117088808-A | Antifungal compound and application thereof | 中国人民解放军海军军医大学 | 2023-11-21 | — | — | CN | disclosed |
| CN-116808035-B | 199596-05-9 application as antitubercular compound | 深圳市第三人民医院(深圳市肝病研究所) | 2023-10-31 | — | — | CN | disclosed |
| CN-116808035-A | 199596-05-9 application as antitubercular compound | 深圳市第三人民医院(深圳市肝病研究所) | 2023-09-29 | — | — | CN | disclosed |
| US-20170362572-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | JANSSEN BIOTECH, INC. (US) | 2017-12-21 | — | — | US | disclosed |
| WO-2017194958-A1 | ASSAY | SCHOFIELD CHRISTOPHER J (GB) | 2017-11-16 | — | — | WO | disclosed |
| EP-3204509-A1 | BIOLUMINESCENT SUCCINATE DETECTION ASSAY | Promega Corporation (US) | 2017-08-16 | — | — | EP | disclosed |
| US-9677117-B2 | Bioluminescent succinate detection assay | PROMEGA CORPORATION (US) | 2017-06-13 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | GILEAD SCIENCES, INC. | 2016-10-20 | — | — | US | disclosed |
| WO-2016057084-A1 | BIOLUMINESCENT SUCCINATE DETECTION ASSAY | PROMEGA CORPORATION (US) | 2016-04-14 | — | — | WO | disclosed |
| US-20160102338-A1 | BIOLUMINESCENT SUCCINATE DETECTION ASSAY | JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT | 2016-04-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170362572-A1 | GENERATION OF HUMAN PLURIPOTENT STEM CELL DERIVED FUNCTIONAL BETA CELLS SHOWING A GLUCOSE-DEPENDENT MITOCHONDRIAL RESPIRATION AND TWO-PHASE INSULIN SECRETION RESPONSE | SLC2A3, SLC2A2, SLC2A1 | KDM4E 3567/4885KDM6B 1339/4885TET3 2268/4885 |
| US-20200155526-A1 | TARGETING LYSINE DEMETHYLASES (KDMS) AS A THERAPEUTIC STRATEGY FOR DIFFUSE LARGE B-CELL LYMPHOMA | KDM1B, KDM4B, DOT1L | KDM4E 7/4885KDM6B 17/4885TET3 125/4885 |
| US-20240139197-A1 | INHIBITION OF KDM5A FOR PROMOTING ANTIGEN PRESENTATION, INCREASING CD8+ T CELL INFILTRATION AND BOOSTING ANTI-TUMOR IMMUNE RESPONSE | KDM5A, KDM5B, KDM5C | KDM4E 16/4885KDM6B 14/4885TET3 168/4885 |
| US-20160303095-A1 | METHODS OF TREATING HEPATITIS B VIRUS | KDM1B, KDM5B, KDM5A | KDM4E 25/4885KDM6B 4/4885TET3 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.